Panobinostat
- Generic Name
- Panobinostat
- Brand Names
- Farydak
- Drug Type
- Small Molecule
- Chemical Formula
- C21H23N3O2
- CAS Number
- 404950-80-7
- Unique Ingredient Identifier
- 9647FM7Y3Z
- Background
Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is mar...
- Indication
Panobinostat is indicated in the treatment of multiple myeloma in combination with dexamethasone and bortezomib in patients who have received 2 previous treatment regimens including bortezomib and an immunomodulatory agent. This indication is approved by accelerated approval based on progression free survival as of February 23, 2015.
- Associated Conditions
- Refractory Multiple Myeloma
- Associated Therapies
- -
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.